These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 25485616)

  • 1. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy.
    Kim J; Li WA; Choi Y; Lewin SA; Verbeke CS; Dranoff G; Mooney DJ
    Nat Biotechnol; 2015 Jan; 33(1):64-72. PubMed ID: 25485616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold.
    Nguyen TL; Cha BG; Choi Y; Im J; Kim J
    Biomaterials; 2020 May; 239():119859. PubMed ID: 32070828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Cancer DNA Vaccine
    Nguyen TL; Yin Y; Choi Y; Jeong JH; Kim J
    ACS Nano; 2020 Sep; 14(9):11623-11636. PubMed ID: 32808762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covalent Conjugation of Peptide Antigen to Mesoporous Silica Rods to Enhance Cellular Responses.
    Dellacherie MO; Li AW; Lu BY; Mooney DJ
    Bioconjug Chem; 2018 Mar; 29(3):733-741. PubMed ID: 29318872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modularly engineered injectable hybrid hydrogels based on protein-polymer network as potent immunologic adjuvant in vivo.
    Giang Phan VH; Duong HTT; Thambi T; Nguyen TL; Turabee MH; Yin Y; Kim SH; Kim J; Jeong JH; Lee DS
    Biomaterials; 2019 Mar; 195():100-110. PubMed ID: 30623788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanically Enhanced Hierarchically Porous Scaffold Composed of Mesoporous Silica for Host Immune Cell Recruitment.
    Choi Y; Jeong JH; Kim J
    Adv Healthc Mater; 2017 Apr; 6(8):. PubMed ID: 28169511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine self-assembling immune matrix is a new delivery platform that enhances immune responses to recombinant HBsAg in mice.
    Grenfell RF; Shollenberger LM; Samli EF; Harn DA
    Clin Vaccine Immunol; 2015 Mar; 22(3):336-43. PubMed ID: 25609075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
    Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
    J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine.
    Sugai T; Mori M; Nakazawa M; Ichino M; Naruto T; Kobayashi N; Kobayashi Y; Minami M; Yokota S
    Vaccine; 2005 Nov; 23(46-47):5450-6. PubMed ID: 16006019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvants may reduce in vivo transfection levels for DNA vaccination in mice leading to reduced antigen-specific CD8+ T cell responses.
    Rose AH; Hoffmann FW; Hara JH; Urschitz J; Moisyadi S; Hoffmann PR; Bertino P
    Hum Vaccin Immunother; 2015; 11(9):2305-11. PubMed ID: 26091088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of CpG into a liposomal vaccine formulation increases the maturation of antigen-loaded dendritic cells and monocytes to improve local and systemic immunity.
    Neeland MR; Elhay MJ; Nathanielsz J; Meeusen EN; de Veer MJ
    J Immunol; 2014 Apr; 192(8):3666-75. PubMed ID: 24646740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma.
    Singh A; Qin H; Fernandez I; Wei J; Lin J; Kwak LW; Roy K
    J Control Release; 2011 Oct; 155(2):184-92. PubMed ID: 21708196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesoporous silica-layered biopolymer hybrid nanofibrous scaffold: a novel nanobiomatrix platform for therapeutics delivery and bone regeneration.
    Singh RK; Jin GZ; Mahapatra C; Patel KD; Chrzanowski W; Kim HW
    ACS Appl Mater Interfaces; 2015 Apr; 7(15):8088-98. PubMed ID: 25768431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RLJ-NE-299A: a new plant based vaccine adjuvant.
    Khajuria A; Gupta A; Singh S; Malik F; Singh J; Suri KA; Satti NK; Qazi GN; Srinivas VK; Gopinathan ; Ella K
    Vaccine; 2007 Mar; 25(14):2706-15. PubMed ID: 16872726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.
    Suleman M; Galea S; Gavard F; Merillon N; Klonjkowski B; Tartour E; Richardson J
    Vaccine; 2011 Aug; 29(35):5892-903. PubMed ID: 21723900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell-based vaccine efficacy: aiming for hot spots.
    Pizzurro GA; Barrio MM
    Front Immunol; 2015; 6():91. PubMed ID: 25784913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response.
    Nguyen CL; Bui JT; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE
    J Immunother; 2001; 24(5):420-9. PubMed ID: 11696697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The cow, the boy and the lymph node--immunological principles for vaccines].
    Munthe LA
    Tidsskr Nor Laegeforen; 2006 Oct; 126(19):2532-7. PubMed ID: 17028635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.
    Dinc G; Pennington JM; Yolcu ES; Lawrenz MB; Shirwan H
    Vaccine; 2014 Sep; 32(39):5035-40. PubMed ID: 25045812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.